false--12-31Q22019truefalse0000059478Lilly Eli & Co16200000008666900000895630000024100000237000001.131.131.291.29324400000322100000667500000020132015
0000059478
2019-01-01
2019-06-30
0000059478
lly:A6.77NotesDueJanuary12036Member
2019-01-01
2019-06-30
0000059478
lly:A718NotesDueJune12025Member
2019-01-01
2019-06-30
0000059478
us-gaap:CommonClassAMember
2019-01-01
2019-06-30
0000059478
lly:A2.125NotesDueJune32030Member
2019-01-01
2019-06-30
0000059478
lly:A1.625NotesDueJune22026Member
2019-01-01
2019-06-30
0000059478
lly:A1.000NotesDueJune22022Member
2019-01-01
2019-06-30
0000059478
2019-07-29
0000059478
2019-04-01
2019-06-30
0000059478
2018-04-01
2018-06-30
0000059478
2018-01-01
2018-06-30
0000059478
us-gaap:AccumulatedOtherComprehensiveIncomeMember
us-gaap:SegmentDiscontinuedOperationsMember
2019-06-30
0000059478
us-gaap:AociAttributableToNoncontrollingInterestMember
us-gaap:SegmentDiscontinuedOperationsMember
2019-06-30
0000059478
us-gaap:SegmentDiscontinuedOperationsMember
2019-01-01
2019-06-30
0000059478
us-gaap:SegmentDiscontinuedOperationsMember
2018-04-01
2018-06-30
0000059478
us-gaap:SegmentDiscontinuedOperationsMember
2018-01-01
2018-06-30
0000059478
us-gaap:SegmentContinuingOperationsMember
2018-04-01
2018-06-30
0000059478
us-gaap:SegmentContinuingOperationsMember
2019-04-01
2019-06-30
0000059478
us-gaap:SegmentDiscontinuedOperationsMember
2019-04-01
2019-06-30
0000059478
us-gaap:SegmentContinuingOperationsMember
2018-01-01
2018-06-30
0000059478
us-gaap:SegmentContinuingOperationsMember
2019-01-01
2019-06-30
0000059478
2018-12-31
0000059478
2019-06-30
0000059478
us-gaap:CommonStockMember
2018-03-31
0000059478
us-gaap:NoncontrollingInterestMember
2019-03-31
0000059478
us-gaap:RetainedEarningsMember
2019-06-30
0000059478
us-gaap:RetainedEarningsMember
2019-03-31
0000059478
us-gaap:AdditionalPaidInCapitalMember
2019-04-01
2019-06-30
0000059478
us-gaap:TreasuryStockMember
2019-06-30
0000059478
us-gaap:CommonStockMember
2018-06-30
0000059478
us-gaap:TreasuryStockMember
2019-03-31
0000059478
us-gaap:RetainedEarningsMember
2018-04-01
2018-06-30
0000059478
us-gaap:NoncontrollingInterestMember
2018-06-30
0000059478
us-gaap:NoncontrollingInterestMember
2019-06-30
0000059478
us-gaap:TreasuryStockMember
2019-04-01
2019-06-30
0000059478
us-gaap:TreasuryStockMember
2018-04-01
2018-06-30
0000059478
us-gaap:AdditionalPaidInCapitalMember
2019-06-30
0000059478
us-gaap:RetainedEarningsMember
2019-04-01
2019-06-30
0000059478
us-gaap:AdditionalPaidInCapitalMember
2018-06-30
0000059478
us-gaap:CommonStockMember
2018-04-01
2018-06-30
0000059478
us-gaap:AdditionalPaidInCapitalMember
2018-03-31
0000059478
us-gaap:NoncontrollingInterestMember
2019-04-01
2019-06-30
0000059478
us-gaap:CommonStockMember
2019-04-01
2019-06-30
0000059478
us-gaap:RetainedEarningsMember
2018-03-31
0000059478
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2019-03-31
0000059478
us-gaap:CommonStockMember
2019-03-31
0000059478
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2019-06-30
0000059478
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2018-06-30
0000059478
us-gaap:AdditionalPaidInCapitalMember
2018-04-01
2018-06-30
0000059478
us-gaap:TrustForBenefitOfEmployeesMember
2019-06-30
0000059478
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2018-03-31
0000059478
us-gaap:CommonStockMember
2019-06-30
0000059478
us-gaap:TreasuryStockMember
2018-06-30
0000059478
us-gaap:TrustForBenefitOfEmployeesMember
2018-03-31
0000059478
us-gaap:RetainedEarningsMember
2018-06-30
0000059478
us-gaap:AdditionalPaidInCapitalMember
2019-03-31
0000059478
us-gaap:NoncontrollingInterestMember
2018-04-01
2018-06-30
0000059478
us-gaap:TrustForBenefitOfEmployeesMember
2019-03-31
0000059478
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2018-04-01
2018-06-30
0000059478
us-gaap:TreasuryStockMember
2018-03-31
0000059478
us-gaap:NoncontrollingInterestMember
2018-03-31
0000059478
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2019-04-01
2019-06-30
0000059478
us-gaap:TrustForBenefitOfEmployeesMember
2018-06-30
0000059478
us-gaap:RetainedEarningsMember
2018-01-01
2018-06-30
0000059478
us-gaap:TreasuryStockMember
2018-12-31
0000059478
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2017-12-31
0000059478
us-gaap:TreasuryStockMember
2019-01-01
2019-06-30
0000059478
us-gaap:CommonStockMember
2019-01-01
2019-06-30
0000059478
us-gaap:TrustForBenefitOfEmployeesMember
2017-12-31
0000059478
us-gaap:TreasuryStockMember
2018-01-01
2018-06-30
0000059478
us-gaap:CommonStockMember
2018-01-01
2018-06-30
0000059478
us-gaap:CommonStockMember
2017-12-31
0000059478
us-gaap:AdditionalPaidInCapitalMember
2019-01-01
2019-06-30
0000059478
us-gaap:RetainedEarningsMember
2018-01-01
0000059478
us-gaap:NoncontrollingInterestMember
2018-01-01
2018-06-30
0000059478
us-gaap:NoncontrollingInterestMember
2018-12-31
0000059478
us-gaap:NoncontrollingInterestMember
2019-01-01
2019-06-30
0000059478
us-gaap:RetainedEarningsMember
2019-01-01
2019-06-30
0000059478
us-gaap:TreasuryStockMember
2017-12-31
0000059478
us-gaap:AdditionalPaidInCapitalMember
2018-12-31
0000059478
us-gaap:CommonStockMember
2018-12-31
0000059478
us-gaap:RetainedEarningsMember
2017-12-31
0000059478
us-gaap:TrustForBenefitOfEmployeesMember
2018-12-31
0000059478
us-gaap:AdditionalPaidInCapitalMember
2018-01-01
2018-06-30
0000059478
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2018-12-31
0000059478
us-gaap:NoncontrollingInterestMember
2017-12-31
0000059478
us-gaap:AdditionalPaidInCapitalMember
2017-12-31
0000059478
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2018-01-01
0000059478
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2018-01-01
2018-06-30
0000059478
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2019-01-01
2019-06-30
0000059478
us-gaap:RetainedEarningsMember
2018-12-31
0000059478
2018-06-30
0000059478
2017-12-31
0000059478
2019-01-01
0000059478
us-gaap:DiscontinuedOperationsDisposedOfBySaleMember
lly:ElancoAnimalHealthIncorporatedMember
2019-03-11
0000059478
us-gaap:AccountingStandardsUpdate201602Member
2019-01-01
0000059478
lly:CymbaltaMember
2018-04-01
2018-06-30
0000059478
lly:CyramzaMember
2019-04-01
2019-06-30
0000059478
lly:ErbituxMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:OncologyMember
2019-04-01
2019-06-30
0000059478
lly:AlimtaMember
country:US
2018-04-01
2018-06-30
0000059478
lly:ForteoMember
country:US
2019-04-01
2019-06-30
0000059478
lly:BasaglarMember
2019-04-01
2019-06-30
0000059478
lly:AlimtaMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:VerzenioMember
2019-04-01
2019-06-30
0000059478
lly:ForteoMember
2019-04-01
2019-06-30
0000059478
lly:OlumiantMember
2018-04-01
2018-06-30
0000059478
lly:EndocrinologyMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:OtherNeuroscienceMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:BasaglarMember
country:US
2019-04-01
2019-06-30
0000059478
lly:CymbaltaMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:JardianceMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:TaltzMember
2018-04-01
2018-06-30
0000059478
lly:AlimtaMember
2018-04-01
2018-06-30
0000059478
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:ImmunologyMember
2019-04-01
2019-06-30
0000059478
lly:ErbituxMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:VerzenioMember
2018-04-01
2018-06-30
0000059478
lly:TrulicityMemberMember
2018-04-01
2018-06-30
0000059478
lly:OncologyMember
country:US
2019-04-01
2019-06-30
0000059478
lly:ErbituxMember
country:US
2019-04-01
2019-06-30
0000059478
lly:TrulicityMemberMember
2019-04-01
2019-06-30
0000059478
lly:JardianceMember
country:US
2019-04-01
2019-06-30
0000059478
lly:StratteraMember
country:US
2018-04-01
2018-06-30
0000059478
lly:OtherNeuroscienceMember
country:US
2019-04-01
2019-06-30
0000059478
lly:HumulinMember
country:US
2018-04-01
2018-06-30
0000059478
lly:NeuroscienceMember
2018-04-01
2018-06-30
0000059478
lly:AlimtaMember
country:US
2019-04-01
2019-06-30
0000059478
lly:CyramzaMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:TrajentaBIMember
country:US
2019-04-01
2019-06-30
0000059478
lly:JardianceMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:TaltzMember
country:US
2018-04-01
2018-06-30
0000059478
lly:JardianceMember
2018-04-01
2018-06-30
0000059478
lly:ZyprexaMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:CymbaltaMember
country:US
2018-04-01
2018-06-30
0000059478
lly:EndocrinologyMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:OtherProductMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:OtherProductMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:TrajentaBIMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:TaltzMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:VerzenioMember
country:US
2018-04-01
2018-06-30
0000059478
lly:OncologyMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
country:US
2019-04-01
2019-06-30
0000059478
lly:EmgalityMember
country:US
2019-04-01
2019-06-30
0000059478
lly:OtherProductMember
2018-04-01
2018-06-30
0000059478
lly:ErbituxMember
country:US
2018-04-01
2018-06-30
0000059478
lly:HumulinMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:NeuroscienceMember
2019-04-01
2019-06-30
0000059478
lly:OtherNeuroscienceMember
country:US
2018-04-01
2018-06-30
0000059478
lly:StratteraMember
2019-04-01
2019-06-30
0000059478
lly:OtherProductTotalMember
2018-04-01
2018-06-30
0000059478
lly:StratteraMember
country:US
2019-04-01
2019-06-30
0000059478
lly:OtherOncologyMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:EmgalityMember
2019-04-01
2019-06-30
0000059478
lly:StratteraMember
2018-04-01
2018-06-30
0000059478
lly:NeuroscienceMember
country:US
2019-04-01
2019-06-30
0000059478
lly:CialisMember
country:US
2019-04-01
2019-06-30
0000059478
lly:OncologyMember
2018-04-01
2018-06-30
0000059478
lly:OlumiantMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:OlumiantMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:CymbaltaMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:OtherOncologyMember
2018-04-01
2018-06-30
0000059478
lly:ForteoMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:HumalogMember
country:US
2019-04-01
2019-06-30
0000059478
lly:OtherEndocrinologyMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:ImmunologyMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:OtherOncologyMember
2019-04-01
2019-06-30
0000059478
lly:HumalogMember
2019-04-01
2019-06-30
0000059478
lly:TrulicityMemberMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:OtherEndocrinologyMember
2019-04-01
2019-06-30
0000059478
lly:EmgalityMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:OtherEndocrinologyMember
country:US
2018-04-01
2018-06-30
0000059478
lly:OtherProductTotalMember
country:US
2018-04-01
2018-06-30
0000059478
lly:OtherEndocrinologyMember
2018-04-01
2018-06-30
0000059478
lly:OtherOncologyMember
country:US
2019-04-01
2019-06-30
0000059478
lly:CyramzaMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:ForteoMember
country:US
2018-04-01
2018-06-30
0000059478
lly:OncologyMember
country:US
2018-04-01
2018-06-30
0000059478
country:US
2018-04-01
2018-06-30
0000059478
lly:OncologyMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:AlimtaMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:AlimtaMember
2019-04-01
2019-06-30
0000059478
lly:OtherOncologyMember
country:US
2018-04-01
2018-06-30
0000059478
lly:ZyprexaMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:ZyprexaMember
country:US
2018-04-01
2018-06-30
0000059478
lly:VerzenioMember
country:US
2019-04-01
2019-06-30
0000059478
lly:OtherProductMember
country:US
2018-04-01
2018-06-30
0000059478
lly:OtherProductTotalMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:NeuroscienceMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:HumulinMember
country:US
2019-04-01
2019-06-30
0000059478
lly:TaltzMember
country:US
2019-04-01
2019-06-30
0000059478
lly:TaltzMember
2019-04-01
2019-06-30
0000059478
lly:BasaglarMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:HumulinMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:OtherEndocrinologyMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:OlumiantMember
country:US
2019-04-01
2019-06-30
0000059478
lly:CialisMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:CialisMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:HumalogMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:EndocrinologyMember
country:US
2018-04-01
2018-06-30
0000059478
lly:StratteraMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:OtherNeuroscienceMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:HumalogMember
2018-04-01
2018-06-30
0000059478
lly:ImmunologyMember
country:US
2018-04-01
2018-06-30
0000059478
lly:ImmunologyMember
2018-04-01
2018-06-30
0000059478
lly:EmgalityMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:HumalogMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:TrajentaBIMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:OtherProductTotalMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:ImmunologyMember
country:US
2019-04-01
2019-06-30
0000059478
lly:TrajentaBIMember
2019-04-01
2019-06-30
0000059478
lly:EndocrinologyMember
2019-04-01
2019-06-30
0000059478
lly:BasaglarMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:JardianceMember
country:US
2018-04-01
2018-06-30
0000059478
lly:OlumiantMember
2019-04-01
2019-06-30
0000059478
lly:ErbituxMember
2018-04-01
2018-06-30
0000059478
lly:ImmunologyMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:NeuroscienceMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:TrajentaBIMember
2018-04-01
2018-06-30
0000059478
lly:OtherEndocrinologyMember
country:US
2019-04-01
2019-06-30
0000059478
lly:CyramzaMember
2018-04-01
2018-06-30
0000059478
lly:EndocrinologyMember
2018-04-01
2018-06-30
0000059478
lly:BasaglarMember
country:US
2018-04-01
2018-06-30
0000059478
lly:CyramzaMember
country:US
2018-04-01
2018-06-30
0000059478
lly:TrulicityMemberMember
country:US
2018-04-01
2018-06-30
0000059478
lly:HumalogMember
country:US
2018-04-01
2018-06-30
0000059478
lly:OlumiantMember
country:US
2018-04-01
2018-06-30
0000059478
lly:CialisMember
2019-04-01
2019-06-30
0000059478
lly:CymbaltaMember
2019-04-01
2019-06-30
0000059478
lly:EmgalityMember
country:US
2018-04-01
2018-06-30
0000059478
lly:EndocrinologyMember
country:US
2019-04-01
2019-06-30
0000059478
lly:OtherOncologyMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:TrulicityMemberMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:ZyprexaMember
country:US
2019-04-01
2019-06-30
0000059478
lly:TaltzMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:OtherProductMember
country:US
2019-04-01
2019-06-30
0000059478
lly:TrulicityMemberMember
country:US
2019-04-01
2019-06-30
0000059478
lly:VerzenioMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:CyramzaMember
country:US
2019-04-01
2019-06-30
0000059478
lly:HumulinMember
2018-04-01
2018-06-30
0000059478
lly:TrajentaBIMember
country:US
2018-04-01
2018-06-30
0000059478
lly:StratteraMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:ErbituxMember
2019-04-01
2019-06-30
0000059478
lly:OtherNeuroscienceMember
2019-04-01
2019-06-30
0000059478
lly:CymbaltaMember
country:US
2019-04-01
2019-06-30
0000059478
lly:BasaglarMember
2018-04-01
2018-06-30
0000059478
lly:JardianceMember
2019-04-01
2019-06-30
0000059478
lly:ZyprexaMember
2018-04-01
2018-06-30
0000059478
lly:OtherNeuroscienceMember
2018-04-01
2018-06-30
0000059478
lly:VerzenioMember
us-gaap:NonUsMember
2018-04-01
2018-06-30
0000059478
lly:HumulinMember
2019-04-01
2019-06-30
0000059478
lly:OtherProductTotalMember
2019-04-01
2019-06-30
0000059478
lly:ForteoMember
2018-04-01
2018-06-30
0000059478
lly:CialisMember
country:US
2018-04-01
2018-06-30
0000059478
lly:ForteoMember
us-gaap:NonUsMember
2019-04-01
2019-06-30
0000059478
lly:OtherProductMember
2019-04-01
2019-06-30
0000059478
lly:ZyprexaMember
2019-04-01
2019-06-30
0000059478
lly:CialisMember
2018-04-01
2018-06-30
0000059478
lly:EmgalityMember
2018-04-01
2018-06-30
0000059478
lly:OtherProductTotalMember
country:US
2019-04-01
2019-06-30
0000059478
lly:NeuroscienceMember
country:US
2018-04-01
2018-06-30
0000059478
lly:TrulicityMemberMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:ErbituxMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:ForteoMember
country:US
2018-01-01
2018-06-30
0000059478
lly:OtherProductTotalMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:OtherEndocrinologyMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:BasaglarMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:TrulicityMemberMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:CialisMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:AlimtaMember
country:US
2019-01-01
2019-06-30
0000059478
lly:OtherOncologyMember
2019-01-01
2019-06-30
0000059478
lly:OncologyMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:CymbaltaMember
country:US
2018-01-01
2018-06-30
0000059478
lly:TrulicityMemberMember
2018-01-01
2018-06-30
0000059478
lly:BasaglarMember
country:US
2018-01-01
2018-06-30
0000059478
lly:EndocrinologyMember
2018-01-01
2018-06-30
0000059478
lly:HumalogMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:EndocrinologyMember
2019-01-01
2019-06-30
0000059478
lly:CymbaltaMember
country:US
2019-01-01
2019-06-30
0000059478
lly:ImmunologyMember
2018-01-01
2018-06-30
0000059478
lly:OtherOncologyMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:CialisMember
country:US
2019-01-01
2019-06-30
0000059478
lly:VerzenioMember
country:US
2019-01-01
2019-06-30
0000059478
lly:StratteraMember
2018-01-01
2018-06-30
0000059478
lly:VerzenioMember
2019-01-01
2019-06-30
0000059478
lly:OtherProductTotalMember
country:US
2018-01-01
2018-06-30
0000059478
lly:ZyprexaMember
country:US
2018-01-01
2018-06-30
0000059478
lly:OtherProductMember
2019-01-01
2019-06-30
0000059478
lly:TrajentaBIMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:ForteoMember
2019-01-01
2019-06-30
0000059478
lly:OtherOncologyMember
2018-01-01
2018-06-30
0000059478
lly:TrulicityMemberMember
country:US
2018-01-01
2018-06-30
0000059478
lly:TaltzMember
2019-01-01
2019-06-30
0000059478
lly:ErbituxMember
country:US
2019-01-01
2019-06-30
0000059478
lly:TrulicityMemberMember
country:US
2019-01-01
2019-06-30
0000059478
lly:JardianceMember
country:US
2019-01-01
2019-06-30
0000059478
lly:TrulicityMemberMember
2019-01-01
2019-06-30
0000059478
lly:HumulinMember
2019-01-01
2019-06-30
0000059478
lly:EndocrinologyMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:OncologyMember
2019-01-01
2019-06-30
0000059478
lly:CialisMember
2018-01-01
2018-06-30
0000059478
lly:VerzenioMember
2018-01-01
2018-06-30
0000059478
lly:ZyprexaMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:HumalogMember
country:US
2019-01-01
2019-06-30
0000059478
lly:TaltzMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:OtherEndocrinologyMember
2018-01-01
2018-06-30
0000059478
lly:TaltzMember
country:US
2019-01-01
2019-06-30
0000059478
lly:ErbituxMember
2018-01-01
2018-06-30
0000059478
lly:BasaglarMember
country:US
2019-01-01
2019-06-30
0000059478
lly:ZyprexaMember
2018-01-01
2018-06-30
0000059478
lly:ErbituxMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:BasaglarMember
2019-01-01
2019-06-30
0000059478
lly:OtherEndocrinologyMember
2019-01-01
2019-06-30
0000059478
lly:NeuroscienceMember
country:US
2018-01-01
2018-06-30
0000059478
lly:CymbaltaMember
2019-01-01
2019-06-30
0000059478
lly:OtherNeuroscienceMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:JardianceMember
2019-01-01
2019-06-30
0000059478
lly:OlumiantMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:CialisMember
country:US
2018-01-01
2018-06-30
0000059478
lly:ZyprexaMember
2019-01-01
2019-06-30
0000059478
lly:OncologyMember
country:US
2019-01-01
2019-06-30
0000059478
lly:TrajentaBIMember
2018-01-01
2018-06-30
0000059478
lly:OtherProductMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:CialisMember
2019-01-01
2019-06-30
0000059478
lly:ForteoMember
2018-01-01
2018-06-30
0000059478
lly:AlimtaMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:TaltzMember
country:US
2018-01-01
2018-06-30
0000059478
lly:CymbaltaMember
2018-01-01
2018-06-30
0000059478
lly:OlumiantMember
2018-01-01
2018-06-30
0000059478
lly:TrajentaBIMember
country:US
2019-01-01
2019-06-30
0000059478
lly:AlimtaMember
2019-01-01
2019-06-30
0000059478
lly:ErbituxMember
2019-01-01
2019-06-30
0000059478
lly:BasaglarMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:CymbaltaMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:TrajentaBIMember
2019-01-01
2019-06-30
0000059478
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:HumulinMember
2018-01-01
2018-06-30
0000059478
lly:VerzenioMember
country:US
2018-01-01
2018-06-30
0000059478
lly:ZyprexaMember
country:US
2019-01-01
2019-06-30
0000059478
lly:HumalogMember
2018-01-01
2018-06-30
0000059478
lly:NeuroscienceMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:OlumiantMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:CyramzaMember
country:US
2018-01-01
2018-06-30
0000059478
lly:NeuroscienceMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:OtherEndocrinologyMember
country:US
2018-01-01
2018-06-30
0000059478
lly:OncologyMember
country:US
2018-01-01
2018-06-30
0000059478
country:US
2019-01-01
2019-06-30
0000059478
lly:EmgalityMember
2019-01-01
2019-06-30
0000059478
lly:TaltzMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:OtherProductMember
2018-01-01
2018-06-30
0000059478
lly:OtherOncologyMember
country:US
2019-01-01
2019-06-30
0000059478
lly:EndocrinologyMember
country:US
2019-01-01
2019-06-30
0000059478
lly:NeuroscienceMember
2019-01-01
2019-06-30
0000059478
lly:HumalogMember
2019-01-01
2019-06-30
0000059478
lly:CyramzaMember
country:US
2019-01-01
2019-06-30
0000059478
lly:OtherEndocrinologyMember
country:US
2019-01-01
2019-06-30
0000059478
lly:EmgalityMember
2018-01-01
2018-06-30
0000059478
lly:CymbaltaMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:EmgalityMember
country:US
2019-01-01
2019-06-30
0000059478
lly:CialisMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:OlumiantMember
2019-01-01
2019-06-30
0000059478
lly:OtherNeuroscienceMember
2018-01-01
2018-06-30
0000059478
lly:JardianceMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:OtherOncologyMember
country:US
2018-01-01
2018-06-30
0000059478
lly:CyramzaMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:CyramzaMember
2018-01-01
2018-06-30
0000059478
lly:StratteraMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:HumalogMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:TaltzMember
2018-01-01
2018-06-30
0000059478
lly:OncologyMember
2018-01-01
2018-06-30
0000059478
lly:HumulinMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:OtherProductTotalMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:NeuroscienceMember
country:US
2019-01-01
2019-06-30
0000059478
lly:BasaglarMember
2018-01-01
2018-06-30
0000059478
lly:OlumiantMember
country:US
2019-01-01
2019-06-30
0000059478
lly:VerzenioMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:OtherProductMember
country:US
2018-01-01
2018-06-30
0000059478
lly:TrajentaBIMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:AlimtaMember
country:US
2018-01-01
2018-06-30
0000059478
lly:ZyprexaMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:ImmunologyMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:HumulinMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:OtherNeuroscienceMember
country:US
2018-01-01
2018-06-30
0000059478
lly:EmgalityMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:OtherProductMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:ImmunologyMember
2019-01-01
2019-06-30
0000059478
lly:ImmunologyMember
country:US
2019-01-01
2019-06-30
0000059478
lly:VerzenioMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:NeuroscienceMember
2018-01-01
2018-06-30
0000059478
lly:AlimtaMember
2018-01-01
2018-06-30
0000059478
lly:OlumiantMember
country:US
2018-01-01
2018-06-30
0000059478
lly:StratteraMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:EmgalityMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:HumalogMember
country:US
2018-01-01
2018-06-30
0000059478
lly:EmgalityMember
country:US
2018-01-01
2018-06-30
0000059478
lly:OtherProductTotalMember
2018-01-01
2018-06-30
0000059478
lly:ImmunologyMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:ForteoMember
country:US
2019-01-01
2019-06-30
0000059478
lly:OtherProductTotalMember
2019-01-01
2019-06-30
0000059478
lly:JardianceMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:TrajentaBIMember
country:US
2018-01-01
2018-06-30
0000059478
lly:JardianceMember
2018-01-01
2018-06-30
0000059478
lly:OtherEndocrinologyMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:ErbituxMember
country:US
2018-01-01
2018-06-30
0000059478
lly:OtherProductTotalMember
country:US
2019-01-01
2019-06-30
0000059478
lly:OtherNeuroscienceMember
country:US
2019-01-01
2019-06-30
0000059478
lly:StratteraMember
country:US
2018-01-01
2018-06-30
0000059478
lly:HumulinMember
country:US
2019-01-01
2019-06-30
0000059478
lly:CyramzaMember
2019-01-01
2019-06-30
0000059478
lly:ForteoMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:JardianceMember
country:US
2018-01-01
2018-06-30
0000059478
lly:AlimtaMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:OtherOncologyMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:StratteraMember
2019-01-01
2019-06-30
0000059478
lly:ForteoMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:OtherNeuroscienceMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:EndocrinologyMember
country:US
2018-01-01
2018-06-30
0000059478
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:OncologyMember
us-gaap:NonUsMember
2018-01-01
2018-06-30
0000059478
lly:ImmunologyMember
country:US
2018-01-01
2018-06-30
0000059478
lly:StratteraMember
country:US
2019-01-01
2019-06-30
0000059478
lly:CyramzaMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:EndocrinologyMember
us-gaap:NonUsMember
2019-01-01
2019-06-30
0000059478
lly:OtherProductMember
country:US
2019-01-01
2019-06-30
0000059478
lly:HumulinMember
country:US
2018-01-01
2018-06-30
0000059478
country:US
2018-01-01
2018-06-30
0000059478
lly:OtherNeuroscienceMember
2019-01-01
2019-06-30
0000059478
lly:CollaborationandOtherRevenueMember
2018-04-01
2018-06-30
0000059478
lly:CollaborationandOtherRevenueMember
2018-01-01
2018-06-30
0000059478
lly:CollaborationandOtherRevenueMember
2019-04-01
2019-06-30
0000059478
us-gaap:ProductMember
2018-01-01
2018-06-30
0000059478
us-gaap:ProductMember
2019-01-01
2019-06-30
0000059478
us-gaap:ProductMember
2018-04-01
2018-06-30
0000059478
us-gaap:ProductMember
2019-04-01
2019-06-30
0000059478
lly:CollaborationandOtherRevenueMember
2019-01-01
2019-06-30
0000059478
lly:OtherForeignCountriesMember
2019-04-01
2019-06-30
0000059478
srt:EuropeMember
2018-01-01
2018-06-30
0000059478
srt:EuropeMember
2018-04-01
2018-06-30
0000059478
lly:OtherForeignCountriesMember
2018-01-01
2018-06-30
0000059478
lly:OtherForeignCountriesMember
2018-04-01
2018-06-30
0000059478
lly:OtherForeignCountriesMember
2019-01-01
2019-06-30
0000059478
country:JP
2019-01-01
2019-06-30
0000059478
srt:EuropeMember
2019-04-01
2019-06-30
0000059478
srt:EuropeMember
2019-01-01
2019-06-30
0000059478
country:JP
2019-04-01
2019-06-30
0000059478
country:JP
2018-04-01
2018-06-30
0000059478
country:JP
2018-01-01
2018-06-30
0000059478
country:US
us-gaap:SalesReturnsAndAllowancesMember
2018-01-01
2018-06-30
0000059478
country:US
us-gaap:SalesReturnsAndAllowancesMember
2018-04-01
2018-06-30
0000059478
us-gaap:RoyaltyMember
2018-01-01
2018-06-30
0000059478
us-gaap:RoyaltyMember
2019-01-01
2019-06-30
0000059478
country:US
us-gaap:SalesReturnsAndAllowancesMember
2019-04-01
2019-06-30
0000059478
us-gaap:RoyaltyMember
2019-04-01
2019-06-30
0000059478
country:US
us-gaap:SalesReturnsAndAllowancesMember
2019-01-01
2019-06-30
0000059478
us-gaap:RoyaltyMember
2018-04-01
2018-06-30
0000059478
lly:LoxoOncologyInc.Member
2019-02-15
0000059478
lly:EddingpharmMember
us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember
lly:LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember
2019-04-30
0000059478
lly:LoxoOncologyInc.Member
2019-02-01
2019-02-28
0000059478
lly:LoxoOncologyInc.Member
us-gaap:ContractBasedIntangibleAssetsMember
2019-02-15
2019-02-15
0000059478
lly:CentrexionTherapeuticsCorporationMember
lly:CNTX0290Member
us-gaap:SubsequentEventMember
2019-07-01
2019-07-31
0000059478
lly:EddingpharmMember
us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember
lly:LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember
2019-04-01
2019-04-30
0000059478
lly:ACImmuneSAMember
2019-01-01
2019-01-31
0000059478
lly:SigilonTherapeuticsMember
2018-04-01
2018-04-30
0000059478
lly:ImmuNextInc.Member
2019-03-01
2019-03-31
0000059478
lly:AurkaPharmaMember
2018-06-01
2018-06-30
0000059478
lly:ARMOBiosciencesInc.Member
2018-06-01
2018-06-30
0000059478
lly:AvidityBiosciencesInc.Member
2019-04-01
2019-04-30
0000059478
lly:OlumiantMember
country:JP
lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredMember
2017-01-01
2017-12-31
0000059478
lly:OlumiantMember
lly:MilestonePaymentsDevelopmentandRegulatoryExpensedMember
2017-01-01
2017-12-31
0000059478
lly:OlumiantMember
lly:MilestonePaymentsDevelopmentandRegulatoryExpensedMember
2018-01-01
2018-12-31
0000059478
lly:OlumiantMember
srt:EuropeMember
lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredMember
2017-01-01
2017-12-31
0000059478
lly:OlumiantMember
lly:MilestonePaymentsDevelopmentandRegulatoryExpensedMember
2016-01-01
2016-12-31
0000059478
lly:OlumiantMember
country:US
lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredMember
2018-01-01
2018-12-31
0000059478
lly:OlumiantMember
lly:MilestonePaymentsSalesBasedMember
2019-01-01
2019-06-30
0000059478
lly:OlumiantMember
us-gaap:RoyaltyAgreementTermsMember
2019-01-01
2019-06-30
0000059478
lly:OlumiantMember
us-gaap:ResearchAndDevelopmentExpenseMember
2019-01-01
2019-06-30
0000059478
lly:TanezumabMember
lly:MilestonePaymentsSalesBasedMember
2019-01-01
2019-06-30
0000059478
lly:TanezumabMember
lly:MilestonePaymentsDevelopmentAndRegulatoryMember
2019-01-01
2019-06-30
0000059478
lly:OlumiantMember
lly:MilestonePaymentsDevelopmentAndRegulatoryMember
2019-01-01
2019-06-30
0000059478
lly:BasaglarMember
lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember
2019-01-01
2019-06-30
0000059478
lly:TrajentaBIMember
lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember
2019-01-01
2019-06-30
0000059478
lly:JardianceMember
lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember
2019-01-01
2019-06-30
0000059478
us-gaap:DiscontinuedOperationsDisposedOfBySaleMember
lly:ElancoAnimalHealthIncorporatedMember
2019-03-11
2019-03-11
0000059478
us-gaap:DiscontinuedOperationsDisposedOfBySaleMember
lly:ElancoAnimalHealthIncorporatedMember
2019-01-01
2019-06-30
0000059478
us-gaap:DiscontinuedOperationsDisposedOfBySaleMember
lly:ElancoAnimalHealthIncorporatedMember
2018-04-01
2018-06-30
0000059478
us-gaap:DiscontinuedOperationsDisposedOfBySaleMember
lly:ElancoAnimalHealthIncorporatedMember
2019-04-01
2019-06-30
0000059478
us-gaap:DiscontinuedOperationsDisposedOfBySaleMember
lly:ElancoAnimalHealthIncorporatedMember
2018-01-01
2018-06-30
0000059478
us-gaap:DiscontinuedOperationsDisposedOfBySaleMember
lly:ElancoAnimalHealthIncorporatedMember
2018-12-31
0000059478
lly:LoxoOncologyInc.Member
2019-01-01
2019-06-30
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2018-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2018-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2019-06-30
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2019-06-30
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2018-12-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2018-12-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2019-06-30
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2019-06-30
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2019-06-30
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2019-06-30
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2018-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
lly:MarketableSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2018-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2018-12-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2019-06-30
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2018-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2019-06-30
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2018-12-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2018-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2019-06-30
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2019-06-30
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2019-06-30
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2019-06-30
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2018-12-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2018-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
lly:EquityMethodAndOtherInvestmentsMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2019-06-30
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2018-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2018-12-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2019-06-30
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2018-12-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2019-06-30
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2019-06-30
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
lly:EquityMethodAndOtherInvestmentsMember
2019-06-30
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2018-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2018-12-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2019-06-30
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2019-06-30
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2019-06-30
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2018-12-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2019-06-30
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2019-06-30
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2018-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2019-06-30
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2019-06-30
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2019-06-30
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2019-06-30
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
lly:MarketableSecuritiesMember
2019-06-30
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2019-06-30
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2019-06-30
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2018-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2018-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2018-12-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2019-06-30
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2019-06-30
0000059478
us-gaap:InterestRateSwapMember
us-gaap:CashFlowHedgingMember
2019-01-01
2019-06-30
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
2019-01-01
2019-06-30
0000059478
lly:HedgedFixedRateDebtMember
us-gaap:NetInvestmentHedgingMember
2018-01-01
2018-06-30
0000059478
us-gaap:InterestRateSwapMember
us-gaap:CashFlowHedgingMember
2019-04-01
2019-06-30
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
2018-04-01
2018-06-30
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
2018-04-01
2018-06-30
0000059478
us-gaap:InterestRateSwapMember
us-gaap:CashFlowHedgingMember
2018-04-01
2018-06-30
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
2019-01-01
2019-06-30
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
2018-01-01
2018-06-30
0000059478
lly:HedgedFixedRateDebtMember
us-gaap:NetInvestmentHedgingMember
2019-01-01
2019-06-30
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
2019-04-01
2019-06-30
0000059478
us-gaap:InterestRateSwapMember
us-gaap:CashFlowHedgingMember
2018-01-01
2018-06-30
0000059478
lly:HedgedFixedRateDebtMember
us-gaap:NetInvestmentHedgingMember
2019-04-01
2019-06-30
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
2019-04-01
2019-06-30
0000059478
lly:HedgedFixedRateDebtMember
us-gaap:NetInvestmentHedgingMember
2018-04-01
2018-06-30
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
2018-01-01
2018-06-30
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:FairValueInputsLevel1Member
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:NondesignatedMember
2019-06-30
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-06-30
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-06-30
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:NondesignatedMember
2019-06-30
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-06-30
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-06-30
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-06-30
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-06-30
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:NondesignatedMember
2018-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-06-30
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-06-30
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-06-30
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:FairValueInputsLevel2Member
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:NondesignatedMember
2019-06-30
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:NondesignatedMember
2018-12-31
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:NondesignatedMember
2018-12-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:FairValueInputsLevel3Member
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-06-30
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:NondesignatedMember
2019-06-30
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-06-30
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-12-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-06-30
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:NondesignatedMember
2018-12-31
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:NondesignatedMember
2018-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-06-30
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:NondesignatedMember
2019-06-30
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-06-30
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-06-30
0000059478
lly:BuyUsDollarSellEuroMember
2019-06-30
0000059478
lly:BuyBritishPoundandSellUSDollarsMember
2019-06-30
0000059478
lly:SwapSwissFrancsToU.S.DollarsMember
2019-06-30
0000059478
lly:SeniorNotesDueMarch2059Member
us-gaap:SeniorNotesMember
2019-02-28
0000059478
lly:SeniorNotesDueMarch2029Member
us-gaap:SeniorNotesMember
2019-02-28
0000059478
lly:SeniorNotesDueMarch2049Member
us-gaap:SeniorNotesMember
2019-02-28
0000059478
lly:ForeignCurrencyDenominatedDebtMember
2019-06-30
0000059478
lly:BuyUSdollarSellJapaneseYenMember
2019-06-30
0000059478
us-gaap:SeniorNotesMember
2019-02-01
2019-02-28
0000059478
lly:ForeignCurrencyDenominatedDebtMember
2018-12-31
0000059478
lly:BuyEuroSellUsDollarMember
2019-06-30
0000059478
lly:SeniorNotesDueMarch2039Member
us-gaap:SeniorNotesMember
2019-02-28
0000059478
lly:SwapU.S.DollarsToBritishPoundsMember
2019-06-30
0000059478
lly:SwapU.S.DollarsToEuroMember
2019-06-30
0000059478
lly:HedgedFixedRateDebtMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-04-01
2018-06-30
0000059478
lly:HedgedFixedRateDebtMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-04-01
2019-06-30
0000059478
us-gaap:InterestRateContractMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-04-01
2019-06-30
0000059478
lly:HedgedFixedRateDebtMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-01-01
2018-06-30
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:NondesignatedMember
2018-04-01
2018-06-30
0000059478
us-gaap:InterestRateContractMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-01-01
2019-06-30
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:NondesignatedMember
2018-01-01
2018-06-30
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:NondesignatedMember
2019-04-01
2019-06-30
0000059478
lly:HedgedFixedRateDebtMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-01-01
2019-06-30
0000059478
us-gaap:InterestRateContractMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-01-01
2018-06-30
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:NondesignatedMember
2019-01-01
2019-06-30
0000059478
us-gaap:InterestRateContractMember
us-gaap:DesignatedAsHedgingInstrumentMember
2018-04-01
2018-06-30
0000059478
us-gaap:TaxYear2015Member
2019-06-30
0000059478
lly:ARMOandAurKaMember
2018-04-01
2018-06-30
0000059478
lly:TaxYears2013To2015Member
2019-04-01
2019-06-30
0000059478
lly:TaxYears2013To2015Member
2019-06-30
0000059478
us-gaap:TaxYear2015Member
2019-01-01
2019-06-30
0000059478
us-gaap:TaxYear2013Member
2019-01-01
2019-06-30
0000059478
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-04-01
2019-06-30
0000059478
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-01-01
2019-06-30
0000059478
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-01-01
2018-06-30
0000059478
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2018-04-01
2018-06-30
0000059478
us-gaap:PensionPlansDefinedBenefitMember
2018-04-01
2018-06-30
0000059478
us-gaap:PensionPlansDefinedBenefitMember
2019-01-01
2019-06-30
0000059478
us-gaap:PensionPlansDefinedBenefitMember
2019-04-01
2019-06-30
0000059478
us-gaap:PensionPlansDefinedBenefitMember
2018-01-01
2018-06-30
0000059478
lly:JapaneseAdministrativeProceedingsMember
2019-06-30
0000059478
lly:EmployeeLitigationMember
country:BR
lly:PlaintiffAppealingDecisionofCourtMember
2019-01-01
2019-06-30
0000059478
lly:DrReddysLabMember
2019-01-01
2019-06-30
0000059478
lly:EmployeeLitigationSimilarLawsuitTwoMember
country:BR
lly:PlaintiffAppealingDecisionofCourtMember
2019-01-01
2019-06-30
0000059478
lly:AdociaS.AMember
2019-06-30
0000059478
lly:EmployeeLitigationMember
country:BR
2019-06-30
2019-06-30
0000059478
lly:EmployeeLitigationSimilarLawsuitOneMember
country:BR
lly:PlaintiffAppealingDecisionofCourtMember
2019-01-01
2019-06-30
0000059478
lly:AlimtaMember
country:US
2019-06-30
0000059478
lly:EmployeeLitigationMember
country:BR
2019-01-01
2019-06-30
0000059478
lly:EmployeeLitigationMember
country:BR
us-gaap:SubsequentEventMember
2019-07-01
2019-07-31
0000059478
lly:EmployeeLitigationMember
country:BR
2018-07-01
2018-07-31
0000059478
lly:InsulinPricingLitigationAndProceedingsMember
2019-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2018-01-01
2018-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
2019-04-01
2019-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
2018-04-01
2018-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2018-01-01
2018-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
2018-01-01
2018-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2019-01-01
2019-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember
2018-01-01
2018-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2018-04-01
2018-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember
2019-01-01
2019-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2019-01-01
2019-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
2019-01-01
2019-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2019-04-01
2019-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2019-04-01
2019-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember
2019-01-01
2019-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2018-04-01
2018-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember
2018-01-01
2018-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember
2019-04-01
2019-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember
2018-04-01
2018-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember
2019-04-01
2019-06-30
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember
2018-04-01
2018-06-30
0000059478
us-gaap:AociAttributableToNoncontrollingInterestMember
2018-01-01
0000059478
us-gaap:AociAttributableToNoncontrollingInterestMember
2018-12-31
0000059478
us-gaap:AociAttributableToNoncontrollingInterestMember
2017-12-31
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2019-01-01
2019-06-30
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2018-01-01
2018-06-30
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
2018-04-01
2018-06-30
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2019-04-01
2019-06-30
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
2019-04-01
2019-06-30
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2018-01-01
2018-06-30
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2019-01-01
2019-06-30
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2018-04-01
2018-06-30
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
2018-01-01
2018-06-30
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2019-01-01
2019-06-30
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2019-04-01
2019-06-30
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2019-04-01
2019-06-30
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2018-04-01
2018-06-30
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2018-01-01
2018-06-30
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
2019-01-01
2019-06-30
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2018-04-01
2018-06-30
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-01-01
2019-06-30
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentDiscontinuedOperationsMember
2019-06-30
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-01-01
2019-06-30
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentDiscontinuedOperationsMember
2019-01-01
2019-06-30
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-12-31
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-01-01
2019-06-30
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentDiscontinuedOperationsMember
2018-12-31
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-06-30
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-01-01
2019-06-30
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-12-31
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2018-12-31
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-06-30
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2019-06-30
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-12-31
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-12-31
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-06-30
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-06-30
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentDiscontinuedOperationsMember
2018-04-01
2018-06-30
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-04-01
2018-06-30
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-04-01
2018-06-30
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-03-31
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-06-30
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-06-30
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-03-31
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-04-01
2018-06-30
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2018-06-30
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-04-01
2018-06-30
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2018-03-31
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-06-30
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-03-31
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentDiscontinuedOperationsMember
2018-03-31
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-03-31
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentDiscontinuedOperationsMember
2018-06-30
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-06-30
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentDiscontinuedOperationsMember
2019-04-01
2019-06-30
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-04-01
2019-06-30
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-04-01
2019-06-30
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-04-01
2019-06-30
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-03-31
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2019-03-31
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-03-31
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentDiscontinuedOperationsMember
2019-03-31
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-04-01
2019-06-30
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-03-31
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-03-31
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-01-01
2018-06-30
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-01-01
2018-06-30
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-01-01
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2017-12-31
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-01-01
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-01-01
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentDiscontinuedOperationsMember
2017-12-31
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-01-01
2018-06-30
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2017-12-31
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-01-01
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-01-01
2018-06-30
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentDiscontinuedOperationsMember
2018-01-01
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2017-12-31
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentDiscontinuedOperationsMember
2018-01-01
2018-06-30
0000059478
2018-01-01
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2017-12-31
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2017-12-31
iso4217:USD
xbrli:shares
xbrli:pure
xbrli:shares
iso4217:USD
iso4217:EUR
iso4217:BRL
lly:case
lly:medicine
iso4217:GBP
lly:company
lly:request
lly:patent
lly:lawsuit
lly:plaintiff
lly:demand
iso4217:JPY
lly:defendant
lly:application
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Form 10-Q
Quarterly Report Under Section 13 or 15(d) of the
Securities Exchange Act of 1934
FOR THE QUARTER ENDED JUNE 30, 2019
COMMISSION FILE NUMBER 001-6351
ELI LILLY AND COMPANY
(Exact name of Registrant as specified in its charter)
|
| | |
Indiana | | 35-0470950 |
(State or other jurisdiction of | | (I.R.S. Employer |
incorporation or organization) | | Identification No.) |
Lilly Corporate Center, Indianapolis, Indiana 46285
(Address of principal executive offices)
Registrant’s telephone number, including area code (317) 276-2000
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes ☒ No ☐
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of a “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
|
| | | | | | | |
Large accelerated filer | ☒ | | | | | Accelerated filer | ☐ |
Non-accelerated filer | ☐ | | | Smaller reporting company | ☐ |
| | | | | | Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
The number of shares of common stock outstanding as of July 29, 2019:
|
| | | |
Class | | Number of Shares Outstanding |
Common | | 965,432,952 |
|
Securities registered pursuant to Section 12(b) of the Exchange Act: |
| | |
Title of Each Class | Trading Symbol | Name of Each Exchange On Which Registered |
Common Stock (no par value) | LLY | New York Stock Exchange |
1.000% Notes Due June 2, 2022 | LLY22 | New York Stock Exchange |
7 1/8% Notes Due June 1, 2025 | LLY25 | New York Stock Exchange |
1.625% Notes Due June 2, 2026 | LLY26 | New York Stock Exchange |
2.125% Notes Due June 3, 2030 | LLY30 | New York Stock Exchange |
6.77% Notes Due January 1, 2036 | LLY36 | New York Stock Exchange |
Eli Lilly and Company
Form 10-Q
For the Quarter Ended June 30, 2019
Table of Contents
Forward-Looking Statements
This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “intend,” “anticipate,” “plan,” “continue,” or similar expressions.
In particular, information appearing under “Management's Discussion and Analysis of Results of Operations and Financial Condition” includes forward-looking statements. Forward-looking statements inherently involve many risks and uncertainties that could cause actual results to differ materially from those projected in these statements. Where, in any forward-looking statement, we (Lilly or the Company) express an expectation or belief as to future results or events, it is based on management's current plans and expectations, expressed in good faith and believed to have a reasonable basis. However, we can give no assurance that any such expectation or belief will result or will be achieved or accomplished. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated:
| |
• | uncertainties in the pharmaceutical research and development process, including with respect to the timing of anticipated regulatory approvals and launches of new products; |
| |
• | market uptake of recently launched products; |
| |
• | competitive developments affecting current products and our pipeline; |
| |
• | the expiration of intellectual property protection for certain of our products; |
| |
• | our ability to protect and enforce patents and other intellectual property; |
| |
• | the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals; |
| |
• | regulatory compliance problems or government investigations; |
| |
• | regulatory actions regarding currently marketed products; |
| |
• | unexpected safety or efficacy concerns associated with our products; |
| |
• | issues with product supply stemming from manufacturing difficulties or disruptions; |
| |
• | regulatory changes or other developments; |
| |
• | changes in patent law or regulations related to data-package exclusivity; |
| |
• | litigation involving past, current, or future products as we are largely self-insured; |
| |
• | unauthorized disclosure, misappropriation, or compromise of trade secrets or other confidential data stored in our information systems, networks, and facilities, or those of third parties with whom we share our data; |
| |
• | changes in tax law, including the impact of United States tax reform legislation enacted in December 2017 and related guidance; |
| |
• | changes in foreign currency exchange rates, interest rates, and inflation; |
| |
• | asset impairments and restructuring charges; |
| |
• | changes in accounting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); |
| |
• | acquisitions and business development transactions and related integration costs; |
| |
• | information technology system inadequacies or operating failures; |
| |
• | reliance on third-party relationships and outsourcing arrangements; and |
| |
• | the impact of global macroeconomic conditions. |
More information on factors that could cause actual results or events to differ materially from those anticipated is included from time to time in our reports filed with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2018, particularly under the caption “Risk Factors”, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019. All forward-looking statements herein speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this report. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this report.
PART I. Financial Information
Item 1. Financial Statements
Consolidated Condensed Statements of Operations
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars and shares in millions, except per-share data)
|
| | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| 2019 | | 2018 | | 2019 | | 2018 |
Revenue (Note 2) | $ | 5,636.7 |
| | $ | 5,585.0 |
| | $ | 10,728.9 |
| | $ | 10,548.8 |
|
Costs, expenses, and other: | | | | | | | |
Cost of sales | 1,124.9 |
| | 1,234.3 |
| | 2,263.6 |
| | 2,398.9 |
|
Research and development | 1,402.2 |
| | 1,271.0 |
| | 2,632.7 |
| | 2,378.5 |
|
Marketing, selling, and administrative | 1,586.3 |
| | 1,485.6 |
| | 3,103.4 |
| | 2,824.3 |
|
Acquired in-process research and development (Note 3) | 25.0 |
| | 1,624.5 |
| | 161.9 |
| | 1,624.5 |
|
Asset impairment, restructuring, and other special charges (Note 6) | — |
| | (25.5 | ) | | 423.9 |
| | 31.3 |
|
Other–net, (income) expense (Note 13) | 32.4 |
| | (46.6 | ) | | (53.6 | ) | | (116.1 | ) |
| 4,170.8 |
|
| 5,543.3 |
|
| 8,531.9 |
|
| 9,141.4 |
|
Income before income taxes | 1,465.9 |
|
| 41.7 |
|
| 2,197.0 |
|
| 1,407.4 |
|
Income taxes (Note 9) | 138.7 |
| | 273.3 |
| | 308.7 |
| | 471.8 |
|
Net income (loss) from continuing operations | 1,327.2 |
| | (231.6 | ) | | 1,888.3 |
| | 935.6 |
|
Net income (loss) from discontinued operations (Note 5) | — |
| | (28.3 | ) | | 3,680.5 |
| | 21.9 |
|
Net income (loss) | $ | 1,327.2 |
|
| $ | (259.9 | ) |
| $ | 5,568.8 |
|
| $ | 957.5 |
|
| | | | | | | |
Earnings (loss) per share: | | | | | | | |
Earnings (loss) from continuing operations - basic | $ | 1.44 |
| | $ | (0.22 | ) | | $ | 1.99 |
| | $ | 0.90 |
|
Earnings (loss) from discontinued operations - basic | — |
| | (0.03 | ) | | 3.87 |
| | 0.02 |
|
Earnings (loss) per share - basic | $ | 1.44 |
| | $ | (0.25 | ) | | $ | 5.86 |
| | $ | 0.92 |
|
| | | | | | | |
Earnings (loss) from continuing operations - diluted | $ | 1.44 |
| | $ | (0.22 | ) | | $ | 1.98 |
| | $ | 0.90 |
|
Earnings (loss) from discontinued operations - diluted | — |
| | (0.03 | ) | | 3.86 |
| | 0.02 |
|
Earnings (loss) per share - diluted | $ | 1.44 |
| | $ | (0.25 | ) | | $ | 5.84 |
| | $ | 0.92 |
|
| | | | | | | |
Shares used in calculation of earnings (loss) per share: | | | | | | | |
Basic | 920.8 |
| | 1,030.2 |
| | 950.4 |
| | 1,039.6 |
|
Diluted | 924.6 |
| | 1,030.2 |
| | 954.2 |
| | 1,041.6 |
|
See notes to consolidated condensed financial statements.
Consolidated Condensed Statements of Comprehensive Income (Loss)
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)
|
| | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| 2019 | | 2018 | | 2019 | | 2018 |
Net income (loss) | $ | 1,327.2 |
| | $ | (259.9 | ) | | $ | 5,568.8 |
| | $ | 957.5 |
|
Other comprehensive income (loss) from continuing operations, net of tax (Note 12) | 87.0 |
| | (511.0 | ) | | 82.9 |
| | (215.4 | ) |
Other comprehensive income (loss) from discontinued operations, net of tax (Note 12) (1) | — |
| | (160.2 | ) | | 56.8 |
| | (69.5 | ) |
Other comprehensive income (loss), net of tax (Note 12) | 87.0 |
| | (671.2 | ) | | 139.7 |
| | (284.9 | ) |
Comprehensive income (loss) | $ | 1,414.2 |
|
| $ | (931.1 | ) |
| $ | 5,708.5 |
|
| $ | 672.6 |
|
See notes to consolidated condensed financial statements.
Consolidated Condensed Balance Sheets
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)
|
| | | | | | | |
| June 30, 2019 | | December 31, 2018 |
Assets | (Unaudited) | | |
Current Assets | | | |
Cash and cash equivalents (Note 7) | $ | 2,290.2 |
| | $ | 7,320.7 |
|
Short-term investments (Note 7) | 77.7 |
| | 88.2 |
|
Accounts receivable, net of allowances of $23.7 (2019) and $24.1 (2018) | 4,612.5 |
| | 4,593.9 |
|
Other receivables | 977.5 |
| | 1,182.9 |
|
Inventories | 3,181.1 |
| | 3,098.1 |
|
Prepaid expenses and other | 2,315.5 |
| | 2,036.7 |
|
Current assets of discontinued operations (Note 5) | — |
| | 2,229.1 |
|
Total current assets | 13,454.5 |
| | 20,549.6 |
|
Investments (Note 7) | 1,852.7 |
| | 2,005.4 |
|
Goodwill | 3,820.1 |
| | 1,366.6 |
|
Other intangibles, net | 6,586.6 |
| | 1,068.0 |
|
Deferred tax assets | 2,507.4 |
| | 2,613.7 |
|
Sundry | 2,052.1 |
| | 1,824.9 |
|
Property and equipment, net of accumulated depreciation of $8,956.3 (2019) and $8,666.9 (2018) | 7,847.5 |
| | 7,996.1 |
|
Operating lease assets (Note 8) | 545.5 |
| | — |
|
Noncurrent assets of discontinued operations (Note 5) | — |
| | 6,484.1 |
|
Total assets | $ | 38,666.4 |
|
| $ | 43,908.4 |
|
Liabilities and Equity | | | |
Current Liabilities | | | |
Short-term borrowings and current maturities of long-term debt | $ | 2,068.6 |
| | $ | 1,102.2 |
|
Accounts payable | 1,198.9 |
| | 1,207.1 |
|
Employee compensation | 588.2 |
| | 955.6 |
|
Sales rebates and discounts | 4,993.7 |
| | 4,849.5 |
|
Dividends payable | 593.9 |
| | 650.8 |
|
Income taxes payable | 222.9 |
| | 393.4 |
|
Other current liabilities | 2,189.2 |
| | 2,036.7 |
|
Current liabilities of discontinued operations (Note 5) | — |
| | 692.8 |
|
Total current liabilities | 11,855.4 |
| | 11,888.1 |
|
Other Liabilities | | | |
Long-term debt | 13,717.6 |
| | 9,196.4 |
|
Noncurrent operating lease liabilities (Note 8) | 503.3 |
| | — |
|
Accrued retirement benefits (Note 10) | 2,723.4 |
| | 2,802.2 |
|
Long-term income taxes payable | 3,485.7 |
| | 3,700.0 |
|
Deferred tax liabilities | 2,380.9 |
| | 1,312.7 |
|
Other noncurrent liabilities | 1,142.8 |
| | 1,357.6 |
|
Noncurrent liabilities of discontinued operations (Note 5) | — |
| | 2,742.3 |
|
Total other liabilities | 23,953.7 |
| | 21,111.2 |
|
Commitments and Contingencies (Note 11) |
| |
|
Eli Lilly and Company Shareholders’ Equity | | | |
Common stock | 603.7 |
| | 661.0 |
|
Additional paid-in capital | 6,534.5 |
| | 6,583.6 |
|
Retained earnings | 4,318.1 |
| | 11,395.9 |
|
Employee benefit trust | (3,013.2 | ) | | (3,013.2 | ) |
Accumulated other comprehensive loss (Note 12) | (5,600.5 | ) | | (5,729.2 | ) |
Cost of common stock in treasury | (62.1 | ) | | (69.4 | ) |
Total Eli Lilly and Company shareholders’ equity | 2,780.5 |
| | 9,828.7 |
|
Noncontrolling interests | 76.8 |
| | 1,080.4 |
|
Total equity | 2,857.3 |
| | 10,909.1 |
|
Total liabilities and equity | $ | 38,666.4 |
| | $ | 43,908.4 |
|
See notes to consolidated condensed financial statements.
Consolidated Condensed Statements of Equity
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Equity of Eli Lilly and Company Shareholders | | |
ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions, except per-share data, and shares in thousands) | Common Stock | | Additional Paid-in Capital | | Retained Earnings | | Employee Benefit Trust | | Accumulated Other Comprehensive Loss | | Common Stock in Treasury | | Noncontrolling Interest |
Shares | | Amount | Shares | | Amount |
Balance at April 1, 2018 | 1,089,234 |
| | $ | 680.8 |
| | $ | 5,758.0 |
| | $ | 16,608.2 |
| | $ | (3,013.2 | ) | | $ | (5,437.5 | ) | | 604 |
| | $ | (69.3 | ) | | $ | 60.8 |
|
Net income (loss) |
|
| |
|
| |
|
| | (259.9 | ) | |
|
| |
|
| |
|
| |
|
| | 4.2 |
|
Other comprehensive loss, net of tax |
|
| |
|
| |
|
| |
|
| |
|
| | (671.2 | ) | |
|
| |
|
| |
|
|
Cash dividends declared per share: $1.13 |
|
| |
|
| |
|
| | (1,148.6 | ) | |
|
| |
|
| |
|
| |
|
| |
|
|
Retirement of treasury shares | (11,735 | ) | | (7.3 | ) | |
|
| | (943.3 | ) | |
|
| |
|
| | (11,735 | ) | | 950.7 |
| |
|
|
Purchase of treasury shares |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| | 11,735 |
| | (950.7 | ) | |
|
|
Issuance of stock under employee stock plans, net | 49 |
| | — |
| | (2.5 | ) | |
|
| |
|
| |
|
| | — |
| | (0.1 | ) | |
|
|
Stock-based compensation |
|
| |
|
| | 70.2 |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
Other |
|
| |
|
| |
|
| | (9.1 | ) | |
|
| |
|
| |
|
| |
|
| | 0.6 |
|
Balance at June 30, 2018 | 1,077,548 |
| | $ | 673.5 |
| | $ | 5,825.7 |
| | $ | 14,247.3 |
| | $ | (3,013.2 | ) | | $ | (6,108.7 | ) | | 604 |
| | $ | (69.4 | ) | | $ | 65.6 |
|
| | | | | | | | | | | | | | | | | |
Balance at April 1, 2019 | 971,363 |
| | $ | 607.1 |
| | $ | 5,756.6 |
| | $ | 4,879.4 |
| | $ | (3,013.2 | ) | | $ | (5,687.5 | ) | | 541 |
| | $ | (62.1 | ) | | $ | 84.7 |
|
Net income (loss) |
|
| |
|
| |
|
| | 1,327.2 |
| |
|
| |
|
| |
|
| |
|
| | (1.1 | ) |
Other comprehensive income, net of tax |
|
| |
|
| |
|
| |
|
| |
|
| | 87.0 |
| |
|
| |
|
| |
|
|
Cash dividends declared per share: $1.29 |
|
| |
|
| |
|
| | (1,178.1 | ) | |
|
| |
|
| |
|
| |
|
| |
|
|
Retirement of treasury shares | (5,430 | ) | | (3.4 | ) | |
|
| | (696.6 | ) | |
|
| |
|
| | (5,430 | ) | | 700.0 |
| |
|
|
Purchase of treasury shares (1) |
|
| |
|
| | 700.0 |
| |
|
| |
|
| |
|
| | 5,430 |
| | (700.0 | ) | |
|
|
Issuance of stock under employee stock plans, net | 24 |
| | — |
| | (1.6 | ) | |
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
Stock-based compensation |
|
| |
|
| | 79.5 |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
Other |
|
| |
|
| |
|
| | (13.8 | ) | |
|
| |
|
| |
|
| |
|
| | (6.8 | ) |
Balance at June 30, 2019 | 965,957 |
| | $ | 603.7 |
| | $ | 6,534.5 |
| | $ | 4,318.1 |
| | $ | (3,013.2 | ) | | $ | (5,600.5 | ) | | 541 |
| | $ | ( |